BIAXIN XL Rx
Generic Name and Formulations:
Clarithromycin 500mg; ext-rel tabs.
Indications for BIAXIN XL:
Mild to moderate susceptible acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia.
Swallow whole. Take with food. 1g once daily. Sinusitis: for 14 days. Bronchitis, pneumonia: for 7 days. Severe renal impairment (CrCl <30mL/min): reduce clarithromycin dose by ½. When moderate or severe renal impairment and concomitant atazanavir or ritonavir: reduce clarithromycin dose by ½ (CrCl 30–60mL/min) or ¾ (CrCl <30mL/min).
Concomitant cisapride, pimozide, ergots, HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (lovastatin or simvastatin). Concomitant colchicine (in renal or hepatic impairment). Cholestatic jaundice/hepatic dysfunction with prior clarithromycin use.
Discontinue immediately if hepatitis or severe hypersensitivity reactions occur. Avoid in known QT prolongation, ventricular cardiac arrhythmia (including torsades de pointes), proarrhythmic conditions (eg, hypokalemia, hypomagnesemia, bradycardia). Coronary artery disease. Myasthenia gravis. Severe renal impairment. Elderly. Pregnancy (Cat.C): not recommended (except when no alternative drugs exist). Nursing mothers.
See Contraindications. Class IA (disopyramide, quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics, or other drugs known to prolong QT interval: not recommended. Sildenafil, tadalafil, vardenafil: not recommended. Antagonized by CYP3A inducers (eg, efavirenz, nevirapine, rifampicin, rifabutin, rifapentine, etravirine); use alternative antibacterial treatment. Doses >1000mg/day should not be coadministered with protease inhibitors. Separate zidovudine dose by at least 2hrs. Potentiated by CYP3A inhibitors (eg, itraconazole, saquinavir, atazanavir, ritonavir). Concomitant atazanavir: see Adults; consider alternative antibacterial therapy for indications other than MAC. May potentiate theophylline, omeprazole, phenytoin, digoxin, midazolam, alprazolam, triazolam, cyclosporine, hexobarbital, tacrolimus, alfentanil, bromocriptine, valproate, carbamazepine, tolterodine, itraconazole, methylprednisolone, cilostazol, vinblastine, quetiapine, maraviroc; monitor these and other drugs metabolized by CYP3A. Myopathy/rhabdomyolysis with statins; max 20mg atorvastatin/day, 40mg pravastatin/day; consider use of statin not dependent on CYP3A metabolism (eg, fluvastatin). Reduce colchicine dose if coadministration is necessary. Hypoglycemia with oral hypoglycemics/insulin; carefully monitor glucose. Oral anticoagulants: frequently monitor INR and prothrombin times. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem, nifedipine).
Abdominal pain, diarrhea, nausea, vomiting, dysguesia; hepatotoxicity, QT prolongation, C. difficile associated diarrhea, hypersensitivity reactions.
XL, tabs (YES); susp (NO)
XL tabs, tabs—60; Biaxin XL-Pac (14 x 500mg XL tabs)—4; Susp—50mL, 100mL
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age